Silymarin, the active constituent of Silybum marianum (milk thistle), and its main component, silybin, are products with well-known hepatoprotective, cytoprotective, antioxidant, and chemopreventative properties. Despite substantial in vitro and in vivo investigations of these flavonolignans, their mechanisms of action and potential toxic effects are not fully defined. In this study we explored important ADME/Tox properties and biochemical interactions of selected flavonolignans using in silico methods. A quantitative structure-activity relationship (QSAR) model based on data from a parallel artificial membrane permeability assay (PAMPA) was used to estimate bioavailability after oral administration. Toxic effects and metabolic transformations were predicted using the knowledge-based expert systems Derek Nexus and Meteor Nexus (Lhasa Ltd). Potential estrogenic activity of the studied silybin congeners was outlined. To address further the stereospecificity of this effect the stereoisomeric forms of silybin were docked into the ligand-binding domain of the human estrogen receptor alpha (ERɑ) (MOE software, CCG). According to our results both stereoisomers can be accommodated into the ERɑ active site, but different poses and interactions were observed for silybin A and silybin B.
Silybum marianum (L.) Gaertn. (milk thistle) is an ancient medicinal plant that has been used for almost 2000 years for treatment of liver and gallbladder disorders of different etiologies [1, 2] . The active component of this herb, silymarin, is a mixture of phenolic compounds, mainly silybin A, silybin B, but also other flavonolignans such as isosilybin A, isosilybin B, silychristin and silydianin, which are located predominantly in the fruit and seeds. The main component of silymarin is silybin, which is a quasi equimolar mixture of two diastereomers A and B (Figure 1 ) [3] .
Today silymarin is best known for its antioxidant and chemoprotective effects on the liver [4] , and is often either prescribed or self-prescribed as a complementary hepatoprotective medicine [5] . It has also gained attention due to its hypocholesterolemic, cardioprotective, neuroactive and neuroprotective properties [4] . Although silymarin is reported as nontoxic in human studies, little is known about its mechanism of action and biochemical interactions [6] . Recent works have explored inhibition and modulation of some drug transporters [7] and nuclear receptors [8] by silybin congeners as well as their biotransformation products [9] . For example, an in vitro study focusing on interactions of flavonolignans with the aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) demonstrated that silymarin has partial estrogenic activity, with silybin B being probably responsible for it [8] . It was outlined that stereochemistry plays an important role for the investigated biological activities and there is a need for studies on the pure forms of the compounds that are otherwise therapeutically used as mixtures [10] . Another important prerequisite for broader and safer therapeutic use of flavonolignans is the better understanding of their metabolism, pharmacokinetics and potential toxic effects.
The pharmaceutical industry has used in silico methods for decades to search, optimize and evaluate drugs [9] . In recent years the in silico ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction is receiving particular attention due to the increased evidence that these pharmacokinetic properties should be considered earlier in the drug discovery process [11] .
In the present study we aimed at exploring important ADME/Tox properties and biochemical interactions of selected flavonolignans (Figures 1 and 2 ) using in silico methods. For estimation of bioavailability after oral administration (gastrointestinal absorption) an in house developed quantitative structure-activity relationship (QSAR) model utilizing data from a parallel artificial membrane permeability assay (PAMPA) was used. Predictions of toxicity and metabolism were performed using knowledge-based expert systems, and molecular modelling studies were applied for investigation of the interactions of the stereoisomeric forms of silybin with the ligand-binding domain (LBD) of the human estrogen receptor alpha (ERα).
In silico estimation of gastrointestinal absorption was performed using a QSAR model for prediction of PAMPA permeability. PAMPA is a high throughput in vitro assay that evaluates transcellular permeation of small drug-like molecules [12] . PAMPA is used in pharmaceutical research to screen for human intestinal absorption since PAMPA permeability has been shown to correlate with both Caco-2 cell permeability and human intestinal absorption [13] . In our study we used a highly predictive QSAR model derived from a data set of nearly 200 diverse drugs with PAMPA permeability coefficients measured at pH 6.5 and 7.4 (Equation 1: n -number of compounds used to derive the model; r 2 -adjusted multiple linear regression correlation coefficient, SEE -standard error of estimate; F -Fisher ratio, LOO q 2 -leave-one-out cross validation correlation coefficient; external validation q 2 -predicted correlation coefficient obtained on a test set of 50 compounds and a training set of 196 compounds [14] ). The predicted values of PAMPA permeability (logPm), as well as the calculated values of the descriptors (logDdistribution coefficient at pH = 7.4; TPSA -topological polar surface area; MW -molecular weight) are shown in Table 1 . According to the in silico prediction of PAMPA permeability the studied silybin congeners may be considered as moderate to highly permeable in the gastrointestinal tract. In silico toxicity and metabolism predictions were performed using the knowledge-based expert systems Derek Nexus and Meteor Nexus [15] . Derek Nexus generates a prediction by comparing the structural features of the target compound with a toxicophore encoded as structural pattern(s) in its knowledge base. The final predictions are derived from a reasoning scheme which takes into account the presence of a toxicophore (structural alert) in the query structure [16] . Based on the alerts detected in the structures of silybin congeners, three potential toxic effects in mammals (chromosome damage in vitro, ERɑ modulation and skin sensitization) are outlined as plausible (Table 2 ), but no stereospecific effects are specified.
Meteor Nexus predicts the metabolic fate of a chemical from its structure [17] . The likelihood of the predicted biotransformation is * The numbers of the compounds are according to the numeration in Table 1 .
assessed by a Site of Metabolism Scoring (SOM) method using experimental data for compounds that match the same biotransformation, have similar molecular weights and are chemically similar around the site of metabolism to the query compound. The two most probable metabolic transformations for the studied compounds are presented: glucuronidation ( Figure 3A ) and oxidative O-demethylation ( Figure 3B ).
A. Glucuronidation B.
Oxidative O-demethylation In order to investigate the interactions of stereoisomeric forms of silybin with the LBD of the ERα a docking study of each of the isomers, silybin A and silybin B, was further performed. It is known that agonists and antagonists stabilize differently the helix 12 (H12) in the LBD C-terminus which plays a crucial role in determining ERɑ interactions with coactivators and corepressors [18] . The antagonist LBD conformation (with H12 position in green, Figure  4 ) was selected for docking of silybins as the agonist conformation (H12 position in magenta, Figure 4) was not large enough to accommodate the silybins (poses were generated with the compounds in unrealistic folded conformations, data not shown).
This selection was additionally justified by the analysis of ERɑ X-ray complexes of partial agonists in the Protein Data Bank (PDB) [19] that both silybin A and silybin B can be accommodated into the ERα active site, but the stereoisomers showed different poses and interactions in the receptor active site. The results obtained from docking with MOE software [20] reveal no specific interactions of silybin A with amino acids in the active site of ERα ( Figure 5 ). In contrast, silybin B forms hydrogen bond (HB) interactions with Leu525, located next to His524 (a residue that the agonist estradiol interacts with, Figure 6 ) and Asp 351 ( Figure 5 ). Unlike the agonist estradiol and the antagonist 4-hydroxytamoxifen (Figure 7) , silybin B does not interact directly with Glu353 and Arg394, but remains close to them and the active water molecule (distances not shown). Similarly to the antagonist 4-hydroxytamoxifen, silybin B interacts with Asp351 (Figure 7 ), but this interaction is through HB, and not through an ionic interaction. Using GOLD software [21, 22] , stereospecific poses of silybin A and silybin B in the active site of ERα were also generated, but inverted orientations were observed with the 10R/11R and 10S/11S atoms of the isomers oriented towards H12, and not towards the inner side of the protein active site (Figure 8 ). In this region, the difference in the orientations of the two ligands is the most noticeable. Both silybins perform HB interactions with Glu353, but only silybin B additionally interacts with Thr347. Our docking results clearly show stereospecific interactions of silybin A and silybin B in the ERα active site, independently of the orientation of the stereoatoms 10R/11R and 10S/11S in the active site (towards H12 or opposite to it). The recorded specific interactions of silybin B in the best docking poses reproduce some of the interactions observed for the agonists and some of the interactions of the antagonists thus implying the behavior of silybin B as a partial agonist. Our docking results are consistent with the in vitro study according to which silybin B and not silybin A is probably responsible for the partial ERα-mediated activity of silymarin [8] . They reveal possible orientations and interactions of these silybins in the receptor active site that, in combination with permeability, toxicity and metabolism predictions, can be useful for the rational modification and design of new natural product derivatives with potential positive effects for the human health.
Experimental
In silico prediction of the gastrointestinal absorption: The predictions were performed using a QSAR model implemented as a workflow in the KNIME platform that is freely accessible to execute in a web browser within the COSMOSTOX webportal (https://knimewebportal.cosmostox.eu/). The descriptors were calculated with ACD/Percepta (logD) (http://www.acdlabs.com/) and CDK KNIME nodes (TPSA/MW) (http://www.knime.org/).
In silico predictions of toxicity and metabolism: The predictions were performed using Derek Nexus v.5.0.1 and Meteor Nexus v.3.0.0 knowledge-based expert systems (Lhasa Ltd.). Derek Nexus provides a level of likelihood for each prediction (certain, probable, plausible, equivocal, doubted, improbable, impossible, open and contradicted). In the present study the reasoning levels of the reported prediction are estimated as "plausible" by the expert system that means "the weight of evidence supports the proposition" [23] . The prediction performed by Meteor Nexus are assessed by SOM Scoring (with Molecular Mass Variance) and the two best scored metabolic transformations of the studied compounds are reported.
Molecular modelling studies: MOE 2015.10 software was used for docking studies, analysis and comparison of protein-ligand interactions and identification of important protein residues. The ERα ligand binding domain (X-ray structure of the ERα with 4-hydroxytamoxifen, PDB ID 3ERT) was initially prepared using the MOE tool "Protonate3D". The physiologically relevant parameters were set during the minimization: temperature = 310 K; pH = 7.4; ion concentration = 0.152 mol/L. The ligands were docked into the binding site of the prepared protein structure using the "Receptor + Solvent" protocol and the binding pocket of the receptor was specified by using the atoms of the co-crystallized ligand (4-hydroxytamoxifen). A rescoring with London dG scoring function was applied to rank the poses of the docked ligands without subsequent refinement and second rescoring. The best scored poses of each ligand with a negative value of the scoring function were kept. The ERα-ligand complexes were analysed using the MOE tool "Ligand Interactions". GOLD v. 5.1 (Cambridge Crystallographic Data Centre Ltd.) software was used for additional docking studies. The ligands were docked into the LBD of the protein and the active site was specified by using the atoms of the co-crystallized ligand (4-hydroxytamoxifen). The docking was performed with an active water molecule in the binding site whose hydrogen positions were allowed to vary during the docking in order to maximise the hydrogen bonding score both from interactions with the protein and the ligand. The docking poses for each of the studied ligands were ranked according to the GoldScore scoring function and the best scored poses were selected. The visualization of the poses and the protein-ligand interactions were performed in MOE software.
